Leo I Gordon

The overarching goal of my involvement in translational research is to improve the outcome of patients with lymphoma. With scientists in the US and abroad, we are currently investigating novel signaling pathways in lymphoma, using cell lines and animal model systems. More specifically, our research focuses on the biology of reactive oxygen species signaling pathways in lymphoma. Active investigations include: 1) the biology of the lactone diterpenoids in lymphoma; 2) the development of all trans retinoic acid (ATRA) and curcumin loaded nanodisks as a drug delivery vehicle in mantle cell lymphoma (MCL), in collaboration with investigators from the Children’s Hospital Research Institute (CHORI) in Oakland, CA 3) The characterization of cholesterol efflux pumps as a target in lymphoma, in collaboration with Dr Colby Shad Thaxton from the Department of Urology and the Northwestern University Center of Cancer Nanotechnology excellence; 4) the study of hypoxia inducible factor (HIF) in lymphoma, in collaboration with Dr. Paul Schumacker. Clinical research interests include the study of novel immune stimulatory strategies following stem cell transplant in lymphoma with collaborators in Israel, Europe and the US, new approaches to the use of radioimmunotherapy (RIT) in lymphoma, and new treatment paradigms based on the basic investigations described above Clinical research studies are carried out through the Northwestern University Lymphoma Program and through national co-operative groups such as the Eastern Cooperative Oncology Group (ECOG), SPORE programs in lymphoma and through the NCI Phase II Consortium in collaboration with investigators at the University of Chicago.